The use of selected 6,8-dioxabicyclo[3.2.1]oct-2-en-4-one and 6,8-dioxabicyclo[3.2.1]oct-3-en-2-one derivatives for the prevention and control of biofilms produced by Pseudomonas sp. 

Protection status: 

Patent application No. P.444225 


The object of the invention is levoglucozenone derivatives for use in the prevention and inhibition of bacterial biofilm formation of Pseudomonas aeruginosa strain PAO1. 


The advantage of the invention is that compounds, for use in inhibiting and preventing bacterial biofilm formation, can be produced in a simple and reproducible manner. Additionally, they are characterized by low toxicity to human and animal organisms. The compounds can be potentially used as one of the components of products for inhibiting biofilm formation by Pseudomonas sp, especially P. aeruginosa – as glucose-lowering compounds in the infection environment, also as active compounds applied on medical biomaterials exposed to the development of Pseudomonas sp infections. 

Stage of work: 

Laboratory basic research.  


To combat bacterial infections caused by Pseudomonas sp, especially P. aeruginosa, by disruption and treatment of bacterial biofilms, which cause a wide spectrum of infections from mild, such as otitis media or otitis externa in healthy individuals, as well as infections associated with cystic fibrosis, causing pneumonia, endocarditis, meningitis, burn wound infections and sepsis. 


@:  sylwia.grzelak@umed.lodz.pl, tel.: 502 447 575 

Ta strona wykorzystuje pliki cookies. Korzystanie z witryny bez zmiany ustawień Twojej przeglądarki oznacza, że będą one umieszczane w Twoim urządzeniu końcowym. We are committed to protecting your privacy and ensuring your data is handled in compliance with the General Data Protection Regulation (GDPR).